BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in …
Over the last 12 months, insiders at BioVie Inc. have bought $27,800 and sold $127,899 worth of BioVie Inc. stock.
On average, over the past 5 years, insiders at BioVie Inc. have bought $158,007 and sold $176,352 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DO CUONG V (President & CEO) — $27,800.
The last purchase of 10,000 shares for transaction amount of $10,000 was made by DO CUONG V (President & CEO) on 2024‑03‑04.
2024-03-04 | President & CEO | 10,000 0.0236% | $1.00 | $10,000 | -58.83% | |||
2023-12-01 | Sale | director | 75,680 0.2029% | $1.69 | $127,899 | -71.22% | ||
2023-11-30 | President & CEO | 10,000 0.0263% | $1.78 | $17,800 | -73.11% | |||
2023-09-05 | Sale | director | 8,560 0.023% | $3.05 | $26,108 | -70.38% | ||
2023-08-22 | Sale | director | 10,805 0.0289% | $3.50 | $37,827 | -70.15% | ||
2023-06-07 | Sale | director | 5,984 0.017% | $5.81 | $34,782 | -69.90% | ||
2023-05-22 | Sale | director | 5,000 0.0137% | $6.50 | $32,506 | -54.90% | ||
2023-03-28 | Sale | director | 7,613 0.0213% | $8.52 | $64,870 | -59.33% | ||
2023-03-27 | Sale | director | 3,371 0.0096% | $8.52 | $28,711 | -58.32% | ||
2021-12-07 | CFO | 2,000 0.0084% | $5.40 | $10,798 | -38.99% | |||
2020-11-03 | director | 2,430 0.0171% | $7.95 | $19,319 | +78.22% | |||
2020-10-30 | director | 2,570 0.0185% | $7.97 | $20,483 | +81.68% | |||
2020-10-21 | director | 5,000 0.0362% | $9.19 | $45,950 | +58.95% | |||
2020-10-15 | director | 15,100 0.1065% | $10.10 | $152,517 | +40.72% | |||
2020-10-09 | director | 282 0.002% | $9.61 | $2,710 | +50.83% | |||
2020-10-07 | director | 4,718 0.0343% | $9.42 | $44,444 | +55.36% | |||
2020-09-22 | director | 15,000 0.263% | $10.00 | $150,000 | +51.62% |
DO CUONG V | President & CEO | 435854 2.453% | $3.06 | 2 | 0 | |
GORLIN STEVE | director | 46358 0.2609% | $3.06 | 7 | 2 | +59.63% |
KIM JOANNE WENDY | CFO | 2000 0.0113% | $3.06 | 1 | 0 | <0.0001% |
Altium Capital Management Lp | $1.59M | 4.93 | 3.01M | New | +$1.59M | 0.19 | |
SABBY MANAGEMENT LLC | $364,277.00 | 1.13 | 689,135 | New | +$364,277.00 | 0.15 | |
The Vanguard Group | $340,722.00 | 1.05 | 644,575 | +83.2% | +$154,734.28 | <0.0001 | |
Cvi Holdings Llc | $317,106.00 | 0.98 | 599,897 | New | +$317,106.00 | 0.33 | |
Renaissance Technologies | $184,000.00 | 0.57 | 347,400 | New | +$184,000.00 | <0.0001 |